CSA stitches ClinicalTrials.gov, openFDA, SEC EDGAR, and FDA substance identity into one asset ↔ sponsor ↔ ticker graph — with a forward catalyst calendar. Anyone can pull one registry; the join is the product.
$499 one-time · for biotech funds, event-driven screening and landscape intelligence · free 150-catalyst sample ↗
One-time snapshot · CSV + JSON · public-domain sources · edition 2026.10
v1 scope: active · industry-sponsored · Phase 3 · cardiometabolic, oncology, immunology — 2,332 trials → 1,881 resolved assets.
Codes, INNs, salts, brands, and combinations collapse to a canonical asset keyed by its FDA-registered active-moiety UNII set — authoritative, not fuzzy. A post-clustering guard makes it hold by construction.
Trial sponsors resolve to the current tradable owner — through acquisitions, to the primary US listing, not the OTC grey line. Comparator and background drugs are flagged, never misattributed.
Two precision-first channels: SEC 8-K disclosure text (PDUFA, AdComm, announced readouts) and ClinicalTrials.gov protocol readouts. Every row carries its source and trial id.
source + nct_id per rowA handful of real upcoming catalysts from the dataset. The full snapshot carries 2,202 forward events, 955 of them linked to 126 listed sponsors, each with a confidence grade and a source URL to re-verify.
| Date | Ticker | Asset | Event | Window | Confidence |
|---|---|---|---|---|---|
| 2026-11-30 | CGON | cretostimogene grenadenorepvec | Readout | Nov 2026 | medium |
| 2026-12-31 | GNLX | olvimulogene nanivacirepvec | Readout | Dec 2026 | medium |
| 2027-01-31 | ABBV | livmoniplimab | Readout | Jan 2027 | medium |
| 2027-03-31 | MDGL | resmetirom | Readout | Mar 2027 | medium |
| 2027-06-30 | AMGN | sotorasib | Readout | Jun 30, 2027 | medium |
| 2027-09-30 | GMAB | rinatabart sesutecan | Readout | Sep 2027 | medium |
| 2027-12-31 | LLY | lebrikizumab | Readout | Dec 2027 | medium |
| 2028-03-10 | PFE | tilrekimig | Readout | Mar 10, 2028 | medium |
Kick the tires first — explore the free 150-catalyst sample on Kaggle or Hugging Face.
Every tracked catalyst and every listed sponsor has its own source-linked page.
asset_master · catalyst_calendar · regulatory_events · scope manifest — CSV + JSON.
Secure card checkout via Stripe · delivered instantly after payment.
Need an invoice or crypto? Contact us.
Need an API or enterprise terms? Use the form.
Data, not investment advice. CSA is information, not a recommendation to buy, sell, or hold any security. Estimated catalyst dates (e.g. protocol primary-completion dates) routinely slip and are graded by confidence — verify anything material against the source URL on each row before acting.
Active, industry-sponsored, Phase 3 interventional trials in cardiometabolic, oncology and immunology: 2,332 trials resolved to 1,881 assets, 603 of them the sponsor's own asset linked to a listed ticker, plus 2,202 forward catalysts, 955 of them linked to 126 listed sponsors. CSV + JSON with a scope manifest. Phase 2 and more areas are the roadmap.
Assets are keyed by their FDA-registered active-moiety UNII set, not fuzzy name matching, and a post-clustering guard means no asset spans two different active moieties — audited to 0 cross-molecule merges on the full run. Uncertain pairs are held for review rather than merged. Precision is the guarantee that matters; a wrong link is the costly error.
Yes. Every primary source is U.S. Government / public domain: ClinicalTrials.gov, openFDA, SEC EDGAR, GSRS/UNII. No license-encumbered source (DrugBank, ChEMBL, MedDRA) is included. Your commercial license ships inside the archive.
They're graded. Company-disclosed exact dates (from 8-Ks) rank above protocol primary-completion estimates, which routinely slip — so they carry a lower confidence and are never presented as commitments. Every row links to its source_url so you can re-verify.
No. CSA is a dataset — information, not advice or a recommendation. See the notice above and the license inside the archive.
API access, more coverage, an enterprise license, or an invoice — reach the desk at csa@dataengineered.io using the form below.
Thanks — we'll reply within one business day.